In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Proteon's Series B round brings in $50mm for the company

Executive Summary

Proteon Therapeutics (developing compounds for cardiovascular and kidney conditions) has raised $38mm through its Series B venture round. Lead investor MPM Capital was joined by fellow backer Vectis Healthcare & Life Sciences Fund and current shareholders TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners, and several original angel investors. MPM gains representation on Proteon's board. The funds will be used to develop Phase I/II PRT201 to improve the health of chronic hemodialysis patients that undergo arteriovenous fistula surgery. Concurrent with the financing, Proteon announced it had granted Novartis an option to buy the company pending the completion of a Phase II trial of the drug candidate.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

UsernamePublicRestriction

Register